GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Cash Flow for Lease Financing

argenx SE (argenx SE) Cash Flow for Lease Financing : $0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is argenx SE Cash Flow for Lease Financing?

argenx SE's Cash Flow for Lease Financing for the three months ended in Dec. 2023 was $0 Mil. argenx SE's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2023 was $0 Mil.

Compared with last quarter ($0 Mil in Sep. 2023 ), argenx SE's Cash Flow for Lease Financing remained the same in Dec. 2023 ($0 Mil).

argenx SE Cash Flow for Lease Financing Historical Data

The historical data trend for argenx SE's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Cash Flow for Lease Financing Chart

argenx SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

argenx SE Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

argenx SE Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of argenx SE's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE (argenx SE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Cash Flow for Lease Financing
Comparable Companies
XBRU:UCB XBRU:TUB XBRU:HYL XBRU:ONWD XBRU:ALIMG XBRU:CYAD XBRU:BIOS XBRU:OXUR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 BNTX BGNE SZSE:300122 ALNY
Traded in Other Exchanges
ARGX:Mexico ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Website
https://www.argenx.com
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.